The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: To describe the roles of apolipoprotein C-III (apoC-III) and apoE in VLDL and LDL metabolism RECENT FINDINGS: ApoC-III can block clearance from the circulation of apolipoprotein B (apoB) lipoproteins, whereas apoE mediates their clearance. Normolipidemia is sustained by hepatic secretion of VLDL and IDL subspecies that contain both apoE and apoC-III (VLDL E+C-III+). Most of this VLDL E+C-III+ is speedily lipolyzed, reduced in apoC-III content, and cleared from the circulation as apoE containing dense VLDL, IDL, and light LDL. In contrast, in hypertriglyceridemia, most VLDL is secreted with apoC-III but without apoE, and so it is not cleared until it loses apoC-III during lipolysis to dense LDL. In normolipidemia, the liver also secretes IDL and large and medium-size LDL, whereas in hypertriglyceridemia, the liver secretes more dense LDL with and without apoC-III. These pathways establish the hypertriglyceridemic phenotype and link it metabolically to dense LDL. Dietary carbohydrate compared with unsaturated fat suppresses metabolic pathways mediated by apoE that are qualitatively similar to those suppressed in hypertriglyceridemia. SUMMARY: The opposing actions of apoC-III and apoE on subspecies of VLDL and LDL, and the direct secretion of LDL in several sizes, establish much of the basic structure of human apoB lipoprotein metabolism in normal and hypertriglyceridemic humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ApoC-III serves as an independent risk marker for CVD due to its central role in lipid metabolism [164, 165].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [165]
In the citing paper
“In hypertriglyceridemia, the liver produces VLDL particles enriched with APOC-III instead of ApoE, which impairs their clearance and promotes the formation of LDL, thereby exacerbating disease progression [24].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [24]
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Mensink, R. P., Zock, P. L., Kester, A. D., & Katan, M. B. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.5.1146 · Cited by 2,811
Dietary Fat Intake and the Risk of Coronary Heart Disease in Women
Hu, F. B., Stampfer, M. J., Manson, J. E., Rimm, E., Colditz, G. A., Rosner, B. A., Hennekens, C. H., & Willett, W. C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711203372102 · Cited by 1,782
Farvid, M. S., Ding, M., Pan, A., Sun, Q., Chiuve, S. E., Steffen, L. M., Willett, W. C., & Hu, F. B. (2014) · Circulation · doi:10.1161/circulationaha.114.010236 · Cited by 567
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Virgil Brown, W., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 491
Aalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · cited 2×
“ApoB metabolism was studied in two patients who had apoC-III deficiency in the context of apoA5/A4/C3/A1 gene cluster mutation [44].”
BackgroundModulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Windler, E., Chao, Y., & Havel, R. J. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70647-4 · Cited by 365
Research works printed but not linked: 1
- Sundaram, 2010, J Lipid Res, 51, 150, 10.1194/m900346-jlr200 · doi:10.1194/m900346-jlr200 · Paper page
Cited by
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Chatuphonprasert, W., Jarukamjorn, K., & Ellinger, I. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01027 · Cited by 269
“To eliminate cholesterol, hepatocytes secrete lipoprotein particles (Sacks, 2015).”
BackgroundSiri-Tarino, P. W., Chiu, S., Bergeron, N., & Krauss, R. M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034449 · Cited by 268
Apolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Metadata
- Authors
- Sacks, F. M.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sacks, Frank M.
- ORCID
- Sacks, Frank M.
- Venue
- Current Opinion in Lipidology
- Published
- 2015-02
- Volume
- 26
- Issue
- 1
- Pages
- 56-63
- ISSN
- 0957-9672 (ISSN-L)
- PMC
- PMC4371603
- OpenAlex
- W2054345063
- Semantic Scholar
- f4f4bb0bd9856c8d91a36423c8c2e19f9a6fd9bb
- Cited by
- 168
- References
- 51
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 7 · 2023: 10 · 2022: 11 · 2021: 25 · 2020: 22 · 2019: 24 · 2018: 17 · 2017: 11 · 2016: 14 · 2015: 11
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- AstraZeneca
- Harvard University
- National Heart, Lung, and Blood Institute (R01HL069376, R01HL070159)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein E, apolipoprotein C-III, VLDL metabolism, LDL metabolism, lipoprotein clearance, hypertriglyceridemia, lipolysis, hepatic lipoprotein secretion, dietary carbohydrates, unsaturated fat
- MeSH terms
- Animals, Apolipoproteins B, Apolipoproteins E, Diet, Humans, Lipoprotein Lipase, Hypertriglyceridemia, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. https://app.cochat.ai/papers/10.1097/mol.0000000000000146
- The paper
- Sacks, F. M. (2015). The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Current Opinion in Lipidology. https://doi.org/10.1097/mol.0000000000000146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.